{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036335","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-11-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.515120+00:00","generated_at":"2026-05-29T13:26:22.382912+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CervoMed's neflamapimod gets FDA Orphan Drug Designation for frontotemporal dementia","bullets":["FDA granted Orphan Drug Designation for neflamapimod to treat frontotemporal dementia (FTD).","Designation recognizes scientific rationale; FTD currently has no approved treatment options.","CervoMed in discussions with clinical thought leaders to design a proof-of-principle FTD study.","Company on track to report topline data from RewinD-LB Phase 2b trial in DLB in December 2024.","Benefits include development assistance, tax credits, fee exemptions, and 7-year post-approval exclusivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036335","json":"https://secwatch.observer/filing/0001437749-24-036335.json","markdown":"https://secwatch.observer/filing/0001437749-24-036335.md","text":"https://secwatch.observer/filing/0001437749-24-036335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924036335/0001437749-24-036335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924036335/crvo20241127_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T13:26:22.382912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}